|

WSD0922-FU Clinical Trials

2 actively recruiting trials

Also known as: WSD0922

Pipeline

Phase 1/2: 2

Top Sponsors

  • Wayshine Biopharm, Inc.2

Indications

  • Lung Cancer2
  • Cancer2
  • EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer1
  • Non-small Cell Lung Cancer (NSCLC)1

Other2 trials

A Study to Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer
Phase 1/2
A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.